Fact sheet: Carnegie Medical

Fund information
Fund name
Carnegie Medical 1A EUR
Fund manager company
Carnegie Asset Management
Fund type
No data available.
Fund managers
  • Angelica Fatourossince 30/06/2008
Fund objective
The investment objective of the fund is to achieve long-term capital growth through global investment in equities of companies operating in the pharmaceutical, biotechnology and medical technology sectors. The emphasis is on large-cap companies, however a considerable part of the portfolio consists of mid and small-cap companies. These are often more difficult to value and less analyzed than large cap companies.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
-13.5%
1 Year rank in sector
21/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.72%
Fund size
£523m
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
148
Top in this sector
Fund name1 Year
Pictet Health5.4%
Fidelity Gbl Health Care5%
BB Medtech3.5%
Variopartner SICAV MVGbMdtcF2.3%
Wellington GlHthcr LS-1.6%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • North America72.3%
    Continental Europe23.9%
    UK3.8%
  • Pharmaceuticals45%
    Biotechnology/Medical38.2%
    Services16.8%
  • North American Equities72.3%
    Europe ex UK Equities23.9%
    UK Equities3.8%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund7.5%-5.1%-4.1%-13.5%30.7%109.1%
Sector4.7%-4.7%-2.8%-8.2%25.2%108.5%
Rank within sector11 / 3216 / 3218 / 3221 / 3111 / 2617 / 24
Quartile2nd2nd3rd3rd2nd3rd
Calendar performance
 YTD - 20162015201420132012
Fund-16%10.7%38.8%31.9%15.4%
Sector-10.3%7.2%28.1%41%16.7%
Rank within sector25 / 3110 / 296 / 2616 / 2420 / 24
Quartile4th2nd1st3rd4th
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
1.09
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.06
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.33
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
18.61
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
6.93
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.18
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.86
Price movement
52 week high105.79
52 week low82.43
Current bid price-
Current offer price-
Current mid price88.62
Region
1North America72.3%
2Continental Europe23.9%
3UK3.8%
Industry sector
1Pharmaceuticals45%
2Biotechnology/Medical38.2%
3Services16.8%
Asset type
1North American Equities72.3%
2Europe ex UK Equities23.9%
3UK Equities3.8%
Individual holdings
1UNITED HEALTH GROUP6.1%
2GILEAD SCIENCES INC6%
3CELGENE CORP5.5%
4JOHNSON & JOHNSON5.4%
5AMGEN INC4.7%
6ACTAVIS INC4.5%
7BIOGEN INC4.4%
8ROCHE HLDG AG4.1%
9CARNEGIE KAPITALFORVALTNING GLOBAL HEALTHCARE FUND CAP3.9%
Management
Fund manager group
Carnegie Asset Management
Fund manager company
Carnegie Asset Management
Fund type
No data available.
Fund objective
The investment objective of the fund is to achieve long-term capital growth through global investment in equities of companies operating in the pharmaceutical, biotechnology and medical technology sectors. The emphasis is on large-cap companies, however a considerable part of the portfolio consists of mid and small-cap companies. These are often more difficult to value and less analyzed than large cap companies.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
Shares
Fund managers
NameSinceBiography
Angelica Fatouros30/06/2008Angelica Fatouros, born 1964, holds an M.Sc. Degree in Biochemical Engineering from the Royal Institute of Technology in Stockholm and a Ph.D. in Pharmaceutical Sciences from the Royal School of Pharmaceutics in Denmark. Angelica is primarily covering large cap pharmaceuticals. Before joining the Healthcare team, Angelica was Head of Nordic Healthcare Research at Carnegie Securities, covering pharmaceuticals and biotechnology stocks, and was top-ranked sector analyst in several client surveys. She has in total 7 years of sell-side experience from Carnegie and Enskilda Securities. Before that she worked for 10 years in pharmaceutical R&D in various positions at Pharmacia and at the Swedish Defence Agency’s research department, FOA (today part of the Karolinska Institute). She has worked both with biotechnology products and small molecular drugs, including developing and filing a biotechnology drug, Refacto (recombinant factor VIII SQ for the bleeding disorder hemophilia), and obtaining four patents in the area of pharmaceutical formulation.
Compliance
UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Germany, Finland, United Kingdom, Luxembourg, Netherlands, Offshore, Sweden
Carnegie Medical 1A EUR
Initial charge5%
Annual charge1.7%
Min single investment£1,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.72%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price88.62
CurrencyEUR
Price updated06/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeH940
Carnegie Medical 1A NOK
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.72%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price333.82
CurrencyNOK
Price updated31/10/2008
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeH938
Carnegie Medical 1A SEK
Initial charge5%
Annual charge1.7%
Min single investment£1,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.72%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price868.41
CurrencySEK
Price updated06/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeH939
Carnegie Medical 1A USD
Initial charge5%
Annual charge1.7%
Min single investment£1,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.72%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price95.12
CurrencyUSD
Price updated06/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeH937
Carnegie Medical 2A NOK
Initial charge3%
Annual charge0.7%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.72%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price929.79
CurrencyNOK
Price updated06/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeH936
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.